A5010432943- Pulmonary Hypertension Research and Treatments
- Cardiovascular Issues in Pregnancy
- Health Systems, Economic Evaluations, Quality of Life
- Interstitial Lung Diseases and Idiopathic Pulmonary Fibrosis
- Lung Cancer Treatments and Mutations
- Cardiovascular Function and Risk Factors
- Gastroesophageal reflux and treatments
- Vascular Anomalies and Treatments
- Venous Thromboembolism Diagnosis and Management
- Transplantation: Methods and Outcomes
- Atrial Fibrillation Management and Outcomes
- Cardiac Arrhythmias and Treatments
- Pharmacology and Obesity Treatment
- Infectious Diseases and Tuberculosis
- Heart Failure Treatment and Management
- Gastric Cancer Management and Outcomes
- Vascular anomalies and interventions
- Liver Disease and Transplantation
- Meta-analysis and systematic reviews
- Statistical Methods in Clinical Trials
- Peptidase Inhibition and Analysis
- Organic Chemistry Synthesis Methods
- Colorectal Cancer Treatments and Studies
- Electroconvulsive Therapy Studies
- Cardiovascular Syncope and Autonomic Disorders
Integris Health
2023-2025
INTEGRIS Baptist Medical Center
2020-2024
The Ohio State University
2012-2013
Pulmonary and Critical Care Associates
2013
Cincinnati VA Medical Center
2009
University of Cincinnati
2009
Treprostinil is a prostacyclin analogue that targets multiple cellular receptors to treat pulmonary arterial hypertension (PAH). In certain scenarios, patients may require aggressive treprostinil titration. Several studies have demonstrated higher doses of lead greater clinical benefit. Data supports successful transitions from parenteral oral treprostinil; however, administration routes, transition duration, and setting vary in the real-world. The EXPEDITE trial (NCT03497689) prospectively...
Oral treprostinil slows disease progression and improves exercise capacity in pulmonary arterial hypertension; however, titration can be prolonged. Published data suggests prostacyclin-naïve patients achieve total daily oral doses of about 6 mg by Week 16, while those on prior parenteral reach higher at the same timepoint.EXPEDITE (NCT03497689), a single-arm, multicenter study, assessed efficacy rapid induction to quickly for treatment hypertension.Parenteral was titrated 2-8 weeks, followed...
PH occurs alone or in association with many disorders. Many patients transthoracic echocardiography (TTE) findings suggesting never receive additional evaluation. Patient characteristics and echocardiographic data associated increased recognition of have not been fully evaluated. We evaluated TTE reports at the Cincinnati Veterans Affairs Medical Center from 2005 to 2006 retrospectively for highly indicative PH: Estimated systolic pulmonary artery pressure (sPAP) ≥40 mmHg, right atrial...
PURPOSE: Pulmonary hypertension (PH) is an underrecognized, potentially fatal cardiopulmonary disease. Many patients with echocardiographic evidence of PH never receive additional evaluation. This study seeks to identify the patient characteristics and associated relevant data that provoke further evaluaton elevated pulmonary artery pressures.